In this white paper, we draw lessons from industries as diverse as food products and toy manufacturing to illustrate how pharmaceutical companies can effectively access innovation outside the traditional in-house R&D model. To read more, click the PDF link below. A version of this article was also published in IN VIVO here.
GLP-1 access is shifting – Are stakeholders ready?
CRA’s Becky Davis examines how these dramatic price reductions, combined with Direct-to-Patient distribution models, may be accelerating employer migration...